This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Kaiser Health News Editor-in-Chief Elisabeth Rosenthal joins John Williams to share her thoughts on the fallout of Elizabeth Holmes’ $700 million biological screening company, Theranos. Holmes is on trial for false promises to her investors, about a blood scan mechanism that didn’t work.